Kymera Therapeutics Completes Enrollment In Global BROADEN2 Phase 2b Trial Of KT-621, Oral STAT6 Degrader, For Treatment Of Moderate To Severe Atopic Dermatitis

Loading news article.

Kymera Therapeutics Completes Enrollment In Global BROADEN2 Phase 2b Trial Of KT-621, Oral STAT6 Degrader, For Treatment Of Moderate To Severe Atopic Dermatitis | WAPE

Kymera Therapeutics Completes Enrollment In Global BROADEN2 Phase 2b Trial Of KT-621, Oral STAT6 Degrader, For Treatment Of Moderate To Severe Atopic Dermatitis

Article summary

Related companies

Comments —